Gout | Treatment Algorithms | Claims Data Analysis | US | 2021
Gout is a chronic arthritic condition caused by elevated serum uric acid (sUA) characterized by intermittent acute flares. Treatment of the painful acute flares is distinct from the chronic management of hyperuricemia with urate-lowering therapies and is not considered in this study. The aim of chronic treatment is to reduce the number and severity of acute flares and damage to the affected joints. Xanthine oxidase inhibitors (XOIs) are the mainstay of chronic gout treatment, with generic allopurinol prescribed extensively. Krystexxa is a highly efficacious biologic drug reserved for later lines of therapy.
What patient shares do key therapies and brands garner by line oftherapy in newly diagnosed gout patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed gout patients?
How has Krystexxa been integrated into the treatment algorithm, and what is its source of business?
What percentage of gout patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
What percentage of gout patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
What are the product-level compliance and persistency rates among drug-treated patients?
Markets covered: United States
Key companies: Horizon Pharma, Takeda Pharmaceuticals, Cardinal Health
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.